A randomized, prospective, open label comparative study of the efficacy of azilsartan and ramipril in the management of hypertension in patients with type-2 diabetes mellitus

Husna Siddiqua, Ghulam Subhani


Background: Patients with diabetes are prone to have hypertension. Hypertension is risk factors for complications of the vascular system, cardiovascular diseases and leads to atherosclerosis. It has been estimated that the diabetics tend to have about two times more risk of having hypertension than the general population. Objective of current study is to study and compare the efficacy of azilsartan and ramipril in the management of Hypertensive patients with type 2 diabetes mellitus

Methods: randomized, prospective, open label comparative study was carried out among 60 known cases of diabetes mellitus type-2 with hypertension. Patients were randomly allocated into two groups: group-A (N=30) taking ACE Inhibitor tablet ramipril 5 mg Once daily orally. Group-B (N=30) taking angiotensin II receptor antagonist tablet azilsartan 40 mg once daily orally. At the commencement of the trial, patients were subjected to thorough clinical examination with necessary investigations and base line values were recorded.

Results: Both the groups were comparable for age, sex and treatment taken. There was a significant reduction in the mean arterial pressure (17.43 for azilsartan group vs. 14.5 for ramipril group) (mmHg), creatinine clearance (mean reduction of 18.8 for azilsartan group vs. 13.94 for ramipril group), and urinary albumin excretion (mean reduction of 29.74 in azilsartan group vs. 17.25 for ramipril group). In azilsartan group the reduction was more in all parameters compared to ramipril group without effecting renal parameters.

Conclusions: Azilsartan was more effective in reducing the mean arterial pressure (mmHg), creatinine clearance as well as urinary albumin excretion in Hypertensive patients with Type 2 diabetes mellitus without effecting renal parameters.


Prospective, Efficacy, Azilsartan, Ramipril, Hypertension, Type -2 diabetes mellitus

Full Text:



American diabetes association. Cardiovascular disease and risk management standards of medical care in diabetes-2016. Diabetes Care. 2016;39(l1): S60-71.

Datta S, Udupa AL. Antihypertensive drug use in patients having co-morbid diabetes: Cross sectional prescription pattern study in a tertiary care hospital. Asian J Pharma Clin Res. 2010;3(4):43-5.

Maniyar Y, Bhixavatimath P, Akkone V. A drug utilization study in the ophthalmology department of a medical college, Karnataka, India. J Clin Diagn Res. 2011;5(1):82-4.

Jain S, Upadhya P, Goel J. A systemic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. Perspect Clin Res. 2015;6(2):86-90.

Mohanty BK, Aswini M, Hasamnis AA, Patil SS, Murthy KSN, Jena SK. Prescription pattern in the department of medicine of a tertiary care hospital in South India. J Clin Diagn Res. 2010;4(1):2047-51.

Zarger AH, Khan AK, Masoodi SR, Laway BA, Wani AI, Bashir MI, et al. Prevalence of type-2 diabetes mellitus and impaired glucose tolerance in the Kashmir valley of the Indian Subcontinent. Diab Res Clin Practice. 2007;47(2):135-46.

Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type2 diabetes incidence and socioeconomic position: a systematic review and meta-analysis. Int J Epidemiol. 2011;40(3):533-6.

Georgiopoulos G, Katsi V, Oikonomou D, Vamvakou G, Koutil E, Laina A, et al. Azilsartan as a potent antihypertensive drug with possible pleiotropic cardio metabolic effects: a review study. Front Pharmacol. 2016;7:235.

Bonner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, et al. Antihypertensive efficacy of the angiotensin receptor blocker Azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor Ramipril. J Human Hypertension. 2013;27: 479-86.

Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C et al. Comparison of the novel angiotensin II receptor blocker Azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens. 2011;13(7):467-72.

Amira CO, Okubadejo NU. Antihypertensive pharmacotherapy in a developing economy: Pattern, acquisition costs and conformity to international guidelines in a tertiary care setting. J Human Hypertension. 2006;20:894-7.

Johnson ML, Singh H. Patterns of antihypertensive therapy among patients with diabetes. J General Internal Med. 2005;20(9):842-6.

Lau GS, Chan JC, Chu PL, Tse DC, Critchely JA. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Annal Pharmacother. 1996;30(3):232-7.